Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single and multiple ascending dose study of BI 1815368 in healthy Japanese males
jRCT2071240039Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial comparing BI 1815368 with Placebo (2 arms). Primary endpoint: Treatment-emergent adverse events related to study drug. Started Sep 2024; status: completed.
02
Drugs
BI 1815368
Beyond the preview
Go deeper on jRCT2071240039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240039.